To evaluate the possible actions of five novels' fluoxetine prodrug derivatives, a number of them have been suggested. The prodrug method aims to increase the number of biopharmaceutical drug deliveries and the drug's pharmacokinetics and/or bioavailability. This strategy has additional benefits, such as therapeutic targeting by enzyme-triggered drug release. The extent of butyrylcholine esterase-mediated activation can be predicted using computational models, which also aid in the development of prodrugs. A variety of computational techniques, such as molecular docking and molecular dynamics simulations, which determined the binding affinities of the five fluoxetine prodrug derivatives molecules to the enzyme binding site by docking them. Computer simulations were performed with GOLD program (CCDC) version 5.43, and the compounds were created with ChemDraw version 22.2 (professional version). They were then evaluated for selectivity with BChE, and a control for comparison was butyrylthiocholine. and for 1nanosecond, SiBioLead server was used to run molecular dynamic simulations of compound A1 complexes with BChE enzyme. RMSD, RMSF, RG results, SASA result, and enzyme energy were estimated during this time. Results showed that the prodrug was activated by BChEenzyme, demonstrating the highest binding energy inside the active cite of the enzyme. PLP fitness values of 86.65, 80,81, and 82.819 were recorded by compounds A1, A2, and A4. This study reveals that fluoxetine prodrug molecular design guided by computational simulations can be more mechanistic and less empirical. Moving forward, the earliest possible stage in the development process should be when prodrugs' action is predicted by molecular modeling tools.
23 July 2026 in Journal of Emergency Medicine, Trauma and Acute Care
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medications, primarily for treating rheumatoid arthritis and other inflammatory conditions. They work by inhibiting the enzyme cyclooxygenase (COX), which converts arachidonic acid into prostaglandins. Non-selective NSAIDs may lead to gastrointestinal side effects and kidney damage due to COX-1 inhibition, whereas selective COX-2 inhibitors provide anti-inflammatory benefits with fewer gastrointestinal risks. However, NSAIDs’ use is often restricted by their potential to cause erosions and ulcers in the gastrointestinal tract. A total of twelve novel Naproxen Derivatives with a 2-azetidinone ring have been proposed to evaluate their potential effectiveness against the cyclo-oxygenase-2-. Molecular docking was conducted with the crystalline structure of COX2 (code:1PXX), using GOLD software (CCDC) version 5.43, computer predictions were made, and the compounds were designed using ChemDraw version 22.2 (professional version). Subsequently, their selectivity with COX2 was assessed, with diclofenac selected as a control for comparison. In silico ADME studies were conducted, revealing the significant potential for binding, and drug-likeness was assessed using the Swiss ADME website. Additionally, Molecular dynamics simulations of compound A3 complexes with COX2 were performed using Schrödinger Suite 2023 software for 100 ns, estimating RMSD, RMSF, Ligand-Protein Contacts, and Ligand Torsion Profile results. Result showing the best binding energy within the receptor pocket, with a promising activity against the COX2 protein receptor. The highest PLP fitness levels were found in compounds A1 and A2 for anti-inflammatory protein (82.554 and 81.777, respectively, average value). All compounds were found to adhere to Lipinski’s rule of five, with high absorption from the gastrointestinal tract. Molecular dynamic results revealed that compound A3 had perfect alignment with the COX-2 receptor. In conclusion, these findings offer a promising direction for the development of effective treatments for inflammation.